Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study
After LPS treatment, the samples were washed with cold PBS and fixed in 4 % paraformaldehyde in PBS for 15 min at room temperature
Redox pathways of the mitochondrion
Sotagliflozin in patients with diabetes and chronic kidney disease
However, these compounds are widely distributed in nature and often suffer from poor bioavailability, raising questions about the translational relevance of their observed effects in vitro
Because this antioxidant is so involved in how our bodies process toxins, its effects can sometimes manifest on the skins surface